Pioglitazone limits cyclosporine nephrotoxicity in rats

International Immunopharmacology

Volumn 6, Issue 13-14, 2006, Pages 1943-1951

  Pereira, Mauricio Galvão ^a   Câmara, Niels Olsen Saraiva ^a,b   Campaholle, Gabriella ^a   Cenedeze, Marcos Antônio ^a   de Paula Antunes Teixeira, Vicente ^c   dos Reis, Marlene Antônia ^c   Pacheco Silva, Alvaro ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

Author keywords

Chronic cyclosporine nephrotoxicity; Pioglitazone; Plasminogen activator inhibitor 1; Smad; Transforming growth factor 1

Indexed keywords

CREATININE; CYCLOSPORIN A; OLIVE OIL; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOWN REGULATION; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ARTERIOLES; BLOOD PRESSURE; BODY WEIGHT; CREATININE; CYCLOSPORINE; DRUG INTERACTIONS; GENE EXPRESSION; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, WISTAR; RNA, MESSENGER; SMAD3 PROTEIN; SMAD7 PROTEIN; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33845225893     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.07.024     Document Type: Article

References (48)

1. United States Renal Data System. USRDS. Annual Data Report. VII. Renal transplantation: access and outcomes. Am J Kidney Dis 30 (1997) 5118
2. Terasaki P.I., Cecka J.M., Gjertson D.W., Takemoto S., Cho Y.W., and Yuge J. Risk rate and long-term kidney transplant survival. Clin Transpl (1996) 443
3. Nankivell B.J., Borrows R.J., Fung C.L.S., O'Connell P.J., Allen R.D.M., and Chapman J.R. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003) 2326-2333
4. Paul L.C. Chronic allograft nephropathy-a model of impaired repair from injury?. Nephrol Dial Transplant 15 (2000) 149-151
5. Remuzzi G., and Perico N. Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int Suppl 52 (1995) S70-S74
6. Mihatsch M.J., Thiel G., and Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 20 (1988) 759-771
7. Young B.A., Burdmann E.A., Johnson R.J., Alpers C.E., Giachelli C.M., Eng E., et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 48 (1995) 439-448
8. Ji P., Si M., Podnos Y., Chow H., Steward E., and Imagawa D.K. Prevention of chronic rejection by pravastatin in a rat kidney transplant model. Transplantation 74 6 (2002) 821-827
9. Amuchastegui S.C., Azzollini N., Mister M., Pezzotta A., Perico N., and Remuzzi G. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 9 (1998) 1948
10. Braun C., Vetter S., Conzelmann T., Schaub M., Kirchengast M., van der Woude F.J., et al. Improvement of chronic renal allograft rejection in rats with the oral endothelin a-receptor antagonist LU135252. Transplantation 68 (1999) 739
11. Feria I., Pichardo I., Juarez P., Ramirez V., Gonzalez M.A., Uribe N., et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 63 1 (2003) 43-52
12. Shihab F.S., Bennett W.M., Yi H., Choi S.O., and Andoh T.F. Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-β1 in chronic cyclosporine nephrotoxicity. Am J Transplant 3 (2003) 1550-1559
13. Shihab F.S., Andoh T.F., Tanner A.M., Noble N.A., Border W.A., Franceschini N., et al. Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy. Kidney Int 49 (1996) 1141-1151
14. Flanders K.C. Smad3 as a mediator of the fibrotic response. Int J Exp Path 85 (2004) 47-64
15. Schiller M., Javelaud D., and Mauviel A. TGF-β-induced smad signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci 35 (2003) 83-92
16. Henry R.R. Thiazolidinediones. Endocrinol Metab Clin North Am 26 (1997) 553-573
17. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
18. Pietruck F., Kribben A., Van T.N., Patschan D., Herget-Rosenthal S., Janssen O., et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int 8 4 (2005) 483-486
19. Luther P., and Baldwin Jr. D. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 4 12 (2004) 2135-2138
20. Quinones M.J., Pampaloni M.H., Juarez B.E., Wang Y.C., Gerardo C., Van Herle K.S., et al. Insulin resistance in healthy Mexican Americans is associated with coronary artery endothelial dysfunction [abstract]. Diabetes 49 Suppl 1 (2000) A146
21. Dobrian A.D., Schriver S.D., Khraibi A.A., and Prewitt R.L. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43 1 (2004) 48-56
22. Dubey R.K., Zhang H.Y., Reddy S.R., Boegehold M.A., and Kotchen T.A. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 265 4 Pt2 (1993) R726-R732
23. Yoshimoto T., Naruse M., Nishikawa M., Naruse K., Tanabe A., Seki T., et al. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 272 6 Pt1 (1997) E989-E996
24. Ma L., Marcantoni C., Linton M.F., Fazio S., and Fogo A.B. Peroxisome proliferator-activated receptor-y agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 59 (2001) 1899-1910
25. Ojo A.O., Held P.J., Port F.K., Wolfe R.A., Leichtman A.B., Young E.W., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 (2003) 931-940
26. Gallagher M.P., Hall B., Craig J., Berry G., Tiller D.J., Eris J., et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 78 11 (2004) 1653-1660
27. Montagnino G., Banfi G., Campise M.R., Passerini P., Aroldi A., Cesana B.M., et al. Impact of chronic allograft nephropathy and subsequent modifications of immunosuppressive therapy on late graft outcomes in renal transplantation. Nephrol Dial Transplant 19 10 (2004) 2622-2629
28. Lo A. Strategies to prevent chronic allograft nephropathy in kidney transplantation: focus on calcineurin inhibitors. Prog Transplant 14 2 (2004) 157-164
29. Weir M.R., Blahut S., Drachenburg C., Young C., Papademitriou J., Klassen D.K., et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 24 4 (2004) 379-386
30. Artz M.A., Hilbrands L.B., Borm G., Assmann K.J., and Wetzels J.F. Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 19 11 (2004) 2852-2857
31. Montanaro D., Gropuzzo M., Tulissi P., Boscutti G., Mioni R., Risaliti A., et al. Renal allograft protection with early angiotensin-converting enzyme inhibitors administration. Transplant Proc 36 3 (2004) 692-694
32. Noris M., Mister M., Pezzotta A., Azzollini N., Cassis P., Benigni A., et al. ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney Int 64 6 (2003) 2253-2261
33. Chung B.H., Li C., Sun B.K., Lim S.W., Ahn K.O., Yang J.H., et al. Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats. Am J Transplant 5 8 (2005) 1856-1867
34. Young B.A., Burdmann E.A., Johnson R.J., Andoh T., Bennett W.M., Couser W.G., et al. Cyclosporin A induced arteriolopathyia a rat model of chronic cyclosporine nephrotoxicity. Kidney Int 48 (1995) 431-438
35. Franceschini N., Alpers C.E., Bennett W.M., and Andoh T.F. Cyclosporine arteriolopathy: effects of drug withdrawal. Am J Kidney Dis 32 (1998) 247-253
36. Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-y, transforming growth factor-β1, and a smad2-dependent mechanism. Diabetes 54 (2005) 811-817
37. Zafiriou S., Stanners S.R., Polhill T.S., Poronnik P., and Pollock C.A. Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses. Kidney Int 65 (2004) 1647-1653
38. Panchapakesan U., Sumual S., Pollock C.A., and Chen X. PPAR gamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol 10 (2005) [abstract]
39. Negro R., Dazzi D., Hassan H., and Pezzarossa A. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol 29 1 (2004) 11-17
40. Nicholas S.B., Aguiniga E., Ren Y., Kim J., Wong J., Govindarajan N., et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 67 (2005) 1297-1307
41. Oda T., Jung Y.O., Kim H.S., Cai X., Lopez-Guisa J.M., Ikeda Y., et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60 (2001) 587-596
42. Nicholas S.B., Kawano Y., Wakino S., Collins A.R., and Hsueh W.A. Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells. Hypertension 37 part 2 (2001) 722-727
43. Marx N., Bourcier T., Sukhova G.K., Libby P., and Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19 3 (1999) 546-551
44. Kato K., Satoh H., Endo Y., Yamada D., Midorikawa S., Sato W., et al. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun 258 2 (1999) 431-435
45. Zirlik A., Leugers A., Lohrmann J., Ernst S., Sobel B.E., Bode C., et al. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost 91 4 (2004) 674-682
46. Wang W., Huang X.R., Li A.G., Liu F., Li J.H., Truong L.D., et al. Signaling mechanism of TGF-â1 in prevention of renal inflammation: role of smad7. J Am Soc Nephrol 16 (2005) 1371-1383
47. Lan H.Y., Mu W., Tomita N., Huang X.R., Li J.H., Zhu H.J., et al. Inhibition of renal fibrosis by gene transfer of inducible smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 14 (2003) 1535-1548
48. Ng Y.Y., Hou C.C., Wang W., Huang X.R., and Lan H.Y. Blockade of NFκB activation and renal inflammation by ultrasound-mediated gene transfer of smad7 in rat remnant kidney. Kidney Int 67 S94 (2005) S83-S91